Oramed Pharmaceuticals – Startup Investor Profile

Oramed Pharmaceuticals develops proprietary Protein Oral Delivery technology for the delivery of drugs.

Location: New York

Country:

Investment Regions:

Investment Stages: late-stage, pre-seed, seed, series-a

Website: http://oramed.com/

AI Reasoning: Oramed Pharmaceuticals’ most recent direct investment activity identified: participation in BioXcel registered direct offering on March 4, 2025 (acquired shares and warrants; partial sale on March 27, 2025). From March 4, 2025 to the reference date is more than 7 months and less than 12 months; however, additional transactions include a real estate loan March 24, 2025 and payments related to OraTech on Feb 27, 2025. The most relevant investment-like activity (equity purchase in BioXcel) occurred March 4, 2025 which is 8 months prior – this places the last investment between 12 and 6 months ago, which maps to low-active. However, the company also completed subsequent financing-related transactions (real estate loan March 24, 2025 and IIA payment Feb 27, 2025) that are not equity investments. Using the defined classification focused on investment rounds and equity purchases, the last qualifying investment was on March 4, 2025, which is between 6 and 12 months ago, so the correct tag is low-active.

Not Active – No known investments in the last 12 months.

Low Activity – Only known investments between the last 12 and 6 months.

Active – Known investments between the last 6 and 3 months.

Very Active – Known investments in the last 3 months.